# World-wide clinical trial about the TYRX Absorbable Antibacterial Envelope

Gepubliceerd: 23-06-2015 Laatst bijgewerkt: 18-08-2022

Medtronic, Inc. is sponsoring the World-wide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT), a randomized, prospective, multi-center, single blinded, post-market, interventional clinical study. This study will evaluate the...

**Ethische beoordeling** Niet van toepassing

**Status** Anders

Type aandoening -

Onderzoekstype Interventie onderzoek

# **Samenvatting**

#### ID

NL-OMON25621

**Bron** 

Nationaal Trial Register

**Verkorte titel** 

**WRAP-IT** 

#### **Aandoening**

Cardiovascular Implantable Electronic Device (CIED) infections

## **Ondersteuning**

**Primaire sponsor:** Medtronic

Overige ondersteuning: Fund = initiator = sponsor

### Onderzoeksproduct en/of interventie

#### **Uitkomstmaten**

#### Primaire uitkomstmaten

The first occurrence of a major CIED infection. CIED infections are defined as (1) superficial cellulitis in the region of the CIED pocket with wound dehiscence, erosion, or purulent drainage, (2) deep incisional or organ/space (generator pocket) surgical site infection that meets the Centers for Disease Control and Prevention criteria, independent from time of surgery, (3) persistent bacteremia, or (4) endocarditis.

<br><br><

- •CIED system removal<br>
- •Any invasive procedure (e.g. pocket opened) without system removal<br/>
- •Treatment with antibiotic therapy if the subject is not a candidate for system removal and infection recurrence after completion of antibiotic therapy or evidence of deep infection with wound dehiscensce, erosion, or purulent drainage<br/>
  br>
- Death

# **Toelichting onderzoek**

#### Doel van het onderzoek

Medtronic , Inc. is sponsoring the World-wide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT), a randomized, prospective, multi-center, single blinded, post-market, interventional clinical study. This study will evaluate the ability of the TYRX envelope to reduce major CIED infections through 12-months post-procedure following CIED generator replacement, upgrade, revision, or de novo CRT-D implant. Additionally, this large device study provides the unique opportunity to prospectively characterize the performance of Medtronic's lead monitoring features in subjects whose CIED system includes a transvenous RV defibrillation lead. Finally, the WRAP-IT study will serve as a post-approval study for those geographies requiring a post-approval study of the TYRX envelope.

#### **Onderzoeksopzet**

The first occurrence of a major CIED infection. [ Time Frame: Implant to 12 months ]

The first occurrence of a major or minor CIED infection [ Time Frame: Implant to 12 months ]

The first occurrence of a CIED procedure related or system related complication [ Time Frame: Implant to 12 months ]

#### Onderzoeksproduct en/of interventie

Active Comparator: TYRX envelope

The Medtronic TYRX Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.

2 - World-wide clinical trial about the TYRX Absorbable Antibacterial Envelope 24-05-2025

Intervention: Device: TYRX Absorbable Antibacterial Envelope

•No Intervention: Control

No TYRX envelope, bare CIED

# Contactpersonen

#### **Publiek**

Medtronic Bakken Research Center - CRHF - Clinical Research

Katrien

Vandersteegen

Endepolsdomein 5

6229 GW

## Wetenschappelijk

Medtronic Bakken Research Center - CRHF - Clinical Research

Katrien

Vandersteegen

Endepolsdomein 5

6229 GW

# **Deelname** eisen

# Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Patient is willing to sign and date the study PIC form
- Patient is at least 18 years of age and meets age requirements per local law
- Patient is planned to undergo at least one of the following:
  - 3 World-wide clinical trial about the TYRX Absorbable Antibacterial Envelope 24-05-2025

- a. Patient has existing CIED and is undergoing IPG (including CRT-P), ICD or CRT-D replacement or upgrade with a new Medtronic generator
- i. Subjects planned to have leads added, or extracted and added for upgrades can be enrolled OR
- b. Patient will undergo a de novo Medtronic CRT-D system implant per approved indications

OR

- c. Patient has existing study eligible Medtronic CIED in which the pocket was not accessed within the last 365 days, and is undergoing pocket or lead revision
- •Willing to provide the contact information for the physician who provides followup for his/her CIED
- •Willing and able to comply with scheduled follow-up and study related activities

# Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- •Known allergy to minocycline or rifampin or their derivatives, or any other known contraindications to implantation of the TYRX envelope.
- •Current therapy with chronic oral immunosuppressive agents or ≥ 20mg/day of Prednisone or equivalent.
- Hemodialysis or peritoneal dialysis.
- Prior Cardiac transplantation or existing Ventricular Assist Device (VAD).
- Require long-term vascular access for any reason.
- Prior history of a CIED infection, other prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months.
- Physical, clinical, or laboratory signs or symptoms consistent with an active infection (including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia)
- •Systemic lupus erythematous, because minocycline has been reported to aggravate this condition
- •Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy
  - 4 World-wide clinical trial about the TYRX Absorbable Antibacterial Envelope 24-05-2025

test within 7 days prior to device procedure

•Participation in another study that may confound the results of this study. Coenrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.

# **Onderzoeksopzet**

#### **Opzet**

Type: Interventie onderzoek

Onderzoeksmodel: Anders

Toewijzing: N.v.t. / één studie arm

Blindering: Enkelblind

Controle: N.v.t. / onbekend

#### **Deelname**

Nederland

Status: Anders

(Verwachte) startdatum: 01-01-2015

Aantal proefpersonen: 7764

Type: Onbekend

# **Ethische beoordeling**

Niet van toepassing

Soort: Niet van toepassing

# **Registraties**

# Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

# Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

# In overige registers

Register ID

NTR-new NL5096 NTR-old NTR5228

Ander register ClinicalTrials.gov : NCT02277990

# Resultaten